Free Trial
NYSE:DVA

DaVita (DVA) Stock Price, News & Analysis

DaVita logo
$129.26 +1.25 (+0.97%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$126.95 -2.31 (-1.79%)
As of 10/24/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DaVita Stock (NYSE:DVA)

Advanced

Key Stats

Today's Range
$128.48
$130.47
50-Day Range
$123.89
$140.31
52-Week Range
$122.93
$179.60
Volume
699,234 shs
Average Volume
605,763 shs
Market Capitalization
$9.24 billion
P/E Ratio
12.71
Dividend Yield
N/A
Price Target
$153.25
Consensus Rating
Reduce

Company Overview

DaVita Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

DVA MarketRank™: 

DaVita scored higher than 96% of companies evaluated by MarketBeat, and ranked 37th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DaVita has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    DaVita has a consensus price target of $153.25, representing about 18.6% upside from its current price of $129.27.

  • Amount of Analyst Coverage

    DaVita has only been the subject of 3 research reports in the past 90 days.

  • Read more about DaVita's stock forecast and price target.
  • Earnings Growth

    Earnings for DaVita are expected to grow by 18.12% in the coming year, from $10.76 to $12.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DaVita is 12.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.64.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DaVita is 12.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.43.

  • Price to Earnings Growth Ratio

    DaVita has a PEG Ratio of 0.92. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    DaVita has a P/B Ratio of 26.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DaVita's valuation and earnings.
  • Percentage of Shares Shorted

    9.61% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 12.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    DaVita does not currently pay a dividend.

  • Dividend Growth

    DaVita does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.61% of the float of DaVita has been sold short.
  • Short Interest Ratio / Days to Cover

    DaVita has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in DaVita has recently decreased by 12.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    DaVita has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for DaVita this week, compared to 13 articles on an average week.
  • Search Interest

    13 people have searched for DVA on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added DaVita to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DaVita insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of DaVita is held by insiders.

  • Percentage Held by Institutions

    90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DaVita's insider trading history.
Receive DVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DVA Stock News Headlines

Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
Barclays Sticks to Their Hold Rating for DaVita (DVA)
See More Headlines

DVA Stock Analysis - Frequently Asked Questions

DaVita's stock was trading at $149.55 at the start of the year. Since then, DVA shares have decreased by 13.6% and is now trading at $129.2650.

DaVita Inc. (NYSE:DVA) announced its quarterly earnings results on Tuesday, August, 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The company's quarterly revenue was up 6.1% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and more.

DaVita's top institutional investors include Wedge Capital Management L L P NC (0.35%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.21%), Assenagon Asset Management S.A. (0.10%) and Robeco Institutional Asset Management B.V. (0.07%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale and Barbara J Desoer.
View institutional ownership trends
.

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/05/2025
Today
10/25/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DVA
CIK
927066
Employees
76,000
Year Founded
1994

Price Target and Rating

High Price Target
$184.00
Low Price Target
$140.00
Potential Upside/Downside
+18.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$10.17
Trailing P/E Ratio
12.71
Forward P/E Ratio
12.01
P/E Growth
0.92
Net Income
$936.34 million
Net Margins
6.35%
Pretax Margin
10.96%
Return on Equity
369.39%
Return on Assets
4.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.39
Quick Ratio
1.34

Sales & Book Value

Annual Sales
$12.82 billion
Price / Sales
0.72
Cash Flow
$19.32 per share
Price / Cash Flow
6.69
Book Value
$4.83 per share
Price / Book
26.76

Miscellaneous

Outstanding Shares
71,500,000
Free Float
70,428,000
Market Cap
$9.24 billion
Optionable
Optionable
Beta
1.13

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NYSE:DVA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners